Plain-English translation of NCT05664516 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This study is testing whether oxytocin, delivered as a nasal spray, can help reduce binge-eating episodes in adults. Binge-eating disorder causes people to eat large amounts of food in a short time, often feeling out of control. Researchers want to see if this medication might help people regain control and eat more normally.
Binge-eating disorder affects many adults and can feel isolating and distressing, but there are limited treatment options available. This trial is exploring whether this medication could offer a new way to help people manage their eating habits and improve their quality of life.
You likely qualify if…
You likely don't qualify if…
You would visit the study clinic at baseline, then at weeks 2, 4, 8, and again at week 16 (8 weeks after treatment ends). At each visit, you would use the nasal spray as directed and have your health monitored through physical exams, blood work, and questions about your eating habits. Half of participants will receive the active medication, and half will receive a placebo (inactive spray), though neither you nor the study staff will know which one you're getting.
AI-generated summary from trial data · Jun 5, 2026 · Not medical advice
United States
Testing effectiveness
Sponsor
Massachusetts General Hospital
Enrollment target
~60 participants
Started
March 2023
Primary completion
December 2026
Age range
18 Years – 70 Years
Last updated on clinicaltrials.gov in May 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Lauren Shabazian, NP
Massachusetts General Hospital
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.